The New York Times, September 11, 2019
Twenty years ago, the fight against cancer seemed as if it were about to take a dramatic turn.
Traditionally, cancer doctors fought the disease with crude weapons, often simply poisoning fast-growing cells whether they were cancerous or healthy. But then a team of researchers hit on a new strategy: drugs targeting proteins produced by cancer cells that seemed necessary to their survival.
One such drug, Gleevec, worked spectacularly in patients with chronic myeloid leukemia. But the clinical trials that followed mostly have produced disappointments.
Continue reading “Why Aren’t Cancer Drugs Better? The Targets Might Be Wrong”